Item 8.01 Other Events.

On January 12, 2022, Immix Biopharma, Inc. (the "Company") announced study data showing that the Company's lead candidate IMX-110 produced a 50% response rate in a first-line-therapy-resistant cancer - soft tissue sarcoma (STS) mouse study, surpassing the STS standard of care doxorubicin's 0% response rate in the same mouse study. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit No.   Description
99.1            Press release dated January 12, 2022




-2-

© Edgar Online, source Glimpses